CASI Pharmaceuticals administers first FOLOTYN dose in China for PTCL treatment
In a significant stride toward addressing the critical medical needs of peripheral T-cell lymphoma (PTCL) patients in China, CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a trailblazer in the biopharmaceutical sector, has achieved a milestone by administering the first dose of FOLOTYN (Pralatrexate Injection) to a patient. This landmark event underscores CASI’s commitment to the development and […]